JP2004533444A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533444A5
JP2004533444A5 JP2002588986A JP2002588986A JP2004533444A5 JP 2004533444 A5 JP2004533444 A5 JP 2004533444A5 JP 2002588986 A JP2002588986 A JP 2002588986A JP 2002588986 A JP2002588986 A JP 2002588986A JP 2004533444 A5 JP2004533444 A5 JP 2004533444A5
Authority
JP
Japan
Prior art keywords
alkyl
composition according
linear alkyl
penetration enhancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002588986A
Other languages
English (en)
Japanese (ja)
Other versions
JP4489356B2 (ja
JP2004533444A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015210 external-priority patent/WO2002092069A1/en
Publication of JP2004533444A publication Critical patent/JP2004533444A/ja
Publication of JP2004533444A5 publication Critical patent/JP2004533444A5/ja
Application granted granted Critical
Publication of JP4489356B2 publication Critical patent/JP4489356B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002588986A 2001-05-11 2002-05-13 浸透促進剤 Expired - Fee Related JP4489356B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29043601P 2001-05-11 2001-05-11
PCT/US2002/015210 WO2002092069A1 (en) 2001-05-11 2002-05-13 Permeation enhancers

Publications (3)

Publication Number Publication Date
JP2004533444A JP2004533444A (ja) 2004-11-04
JP2004533444A5 true JP2004533444A5 (US07794700-20100914-C00152.png) 2005-12-22
JP4489356B2 JP4489356B2 (ja) 2010-06-23

Family

ID=23115989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002588986A Expired - Fee Related JP4489356B2 (ja) 2001-05-11 2002-05-13 浸透促進剤
JP2002589499A Pending JP2004537516A (ja) 2001-05-11 2002-05-13 アンチセンス浸透促進剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2002589499A Pending JP2004537516A (ja) 2001-05-11 2002-05-13 アンチセンス浸透促進剤

Country Status (6)

Country Link
US (3) US20030176379A1 (US07794700-20100914-C00152.png)
EP (2) EP1392272B1 (US07794700-20100914-C00152.png)
JP (2) JP4489356B2 (US07794700-20100914-C00152.png)
AT (1) ATE547095T1 (US07794700-20100914-C00152.png)
CA (2) CA2447444A1 (US07794700-20100914-C00152.png)
WO (2) WO2002092616A1 (US07794700-20100914-C00152.png)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
EP1390024A4 (en) * 2001-05-11 2010-02-17 Merrion Res Iii Ltd ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
EP1718274A2 (en) * 2004-01-26 2006-11-08 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
TW200950799A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
MX348705B (es) 2008-09-17 2017-06-26 Chiasma Inc Composiciones farmacéuticas y métodos de administración relacionados.
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2012135736A2 (en) 2011-04-01 2012-10-04 Isis Pharmaceuticals, Inc. Modulation of signal transducer and activator of transcription 3 (stat3) expression
KR20140097398A (ko) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
BR112015006176B1 (pt) 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
CA3023451A1 (en) * 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2019055539A1 (en) * 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
EP3982953A4 (en) * 2019-06-14 2023-07-19 The Trustees of Princeton University DIHYDROMYRICETIN AND PERMEABILIZING AGENT FORMULATIONS
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953626A (en) 1961-04-25 1964-03-25 Meito Sangyo Kk Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
JPS5131687A (en) * 1974-09-11 1976-03-17 Shin Nippon Rika Kk Shitsujunzai
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS5973600A (ja) 1982-10-19 1984-04-25 Okayasu Shoten:Kk 排卵誘発剤
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
AU581177B2 (en) 1983-05-31 1989-02-16 Choong-Gook Jang Dry direct compression compositions for controlled release dosage forms
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
EP0208417A3 (en) * 1985-06-12 1989-09-06 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US6051609A (en) * 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4789547A (en) 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
US4910205A (en) * 1988-05-02 1990-03-20 Schering Corporation Transdermal delivery of loratadine
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ZA898331B (en) 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
JPH02207018A (ja) 1989-02-07 1990-08-16 Kao Corp 皮膚外用剤
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
JPH03275633A (ja) 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
DE4115849A1 (de) * 1991-05-15 1992-11-19 Lohmann Therapie Syst Lts Penetrationsfoerdernde substanz
DE4116912A1 (de) * 1991-05-18 1992-11-26 Schering Ag Mittel zur transdermalen applikation enthaltend ergolin-derivate
CA2070061C (en) 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
JP3026030B2 (ja) * 1991-07-13 2000-03-27 株式会社リコー カメラの測距装置
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
JP3190441B2 (ja) 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
RU2068689C1 (ru) 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Способ получения таблеток парацетамола
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DK0744941T3 (da) 1994-02-16 2003-09-29 Abbott Lab Fremgangsmåde til fremstilling af findelte farmaceutiske formuleringer
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
IL110024A (en) 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
KR100413202B1 (ko) 1994-11-17 2004-04-13 도레이 가부시끼가이샤 경피흡수제제
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
CA2220451A1 (en) * 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
CN1231592A (zh) 1996-10-30 1999-10-13 瑟垃技术有限公司 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
ATE293960T1 (de) * 1997-02-28 2005-05-15 Minnesota Mining & Mfg Transdermale vorrichtung zur verabreichungvon von testosteron
JPH1112177A (ja) * 1997-06-25 1999-01-19 Teikoku Seiyaku Co Ltd 安定なアスピリン含有外用製剤
US6262161B1 (en) * 1997-06-26 2001-07-17 The Dow Chemical Company Compositions having improved ignition resistance
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
IL121269A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Compositions and methods for reversibly increasing permeability of biomembranes
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
JP4181232B2 (ja) 1997-07-18 2008-11-12 帝國製薬株式会社 ジクロフェナクナトリウム含有油性外用貼付製剤
JP4372347B2 (ja) * 1998-03-11 2009-11-25 あすか製薬株式会社 発泡性腸溶製剤
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
EP1469009A2 (en) * 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
WO2000022909A2 (en) * 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
ATE386508T1 (de) 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6153209A (en) * 1999-09-28 2000-11-28 The Procter & Gamble Company Article having a transferable breathable skin care composition thereon
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6379960B1 (en) 2000-12-06 2002-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of damage-specific DNA binding protein 2, p48 expression
EP1390024A4 (en) 2001-05-11 2010-02-17 Merrion Res Iii Ltd ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna

Similar Documents

Publication Publication Date Title
JP2004533444A5 (US07794700-20100914-C00152.png)
JP2002541233A5 (US07794700-20100914-C00152.png)
JP2002517491A5 (US07794700-20100914-C00152.png)
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
EP1535909A3 (en) Cyclic amine derivatives and their use as drugs
JP2004518723A5 (US07794700-20100914-C00152.png)
JP2003519676A5 (US07794700-20100914-C00152.png)
JP2002533472A5 (US07794700-20100914-C00152.png)
TR200100137T2 (tr) Obesitenin ve başka bozuklukların tedavisinde yararlı nöropeptit Y Y5 reseptörü için ligandlar olarak N-ikameli aminotetralinler.
JP2005511699A5 (US07794700-20100914-C00152.png)
JP2004529953A5 (US07794700-20100914-C00152.png)
EP1772142A3 (en) Organic compounds
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
JP2003523927A5 (US07794700-20100914-C00152.png)
RU94019972A (ru) Гетероариламины, способ их получения, фармацевтическая композиция и способ ингибирования ацетилхолинэстеразы
JP2008545718A5 (US07794700-20100914-C00152.png)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2004537516A5 (US07794700-20100914-C00152.png)
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
JP2002527414A5 (US07794700-20100914-C00152.png)
RU2002130247A (ru) Производные оксадиазола, обладающие противоопухолевым действием
JP2005536503A5 (US07794700-20100914-C00152.png)
EP0992509A3 (en) Novel macrolide derivatives
EA200970387A1 (ru) Соль п-толуолсульфокислоты 5-амино-3-(2`-о-ацетил-3`-дезокси-бета-d-рибофуранозил)-3н-тиазоло[4,5-d]пиримидин-2-она и способы получения
RU2002123641A (ru) С-4 карбонатсодержащие таксаны